Danaher Corporation announced today that it entered into a definitive transaction agreement to acquire Nobel Biocare Holding AG, a world leader in implant dentistry. For the past 40 years, Nobel Biocare has established itself as a pioneer in many different aspects of implant dentistry. Implants and prosthetics is one of the most exciting categories in dentistry today and offers a unique opportunity for dental professionals to deliver long-term solutions.
Nobel Biocare will operate as a stand-alone company within Danaher’s dental platform and will maintain its own brand and identity. Implant Direct will remain as a stand-alone joint venture with no change in its go-to market strategy.
“We will continue to invest in a wide range of dental technologies and innovations to better serve our customers. Bringing Nobel Biocare’s deep expertise in implant dentistry, digital prosthetics and software solutions together with our extensive knowledge in 3D imaging, intraoral scanning and digital restorative solutions will further enable us to optimize and integrate workflows. This will lead to better clinical outcomes, shorter treatment times and fewer office visits to the benefit of patients and dental practitioners,” said Henk van Duijnhoven, Senior Vice President of Danaher’s dental platform. “This combination will further support our business strategy and position our dental business for future growth.”
“Nobel Biocare’s leadership team has done an outstanding job creating a strong platform for future growth over the last couple of years,” van Duijnhoven added. “Our team is excited to work with CEO Richard Laube and the Nobel Biocare team to build on their efforts toward continued innovation, growth and business improvement. We look forward to welcoming all Nobel Biocare’s associates, customers and key opinion leaders to the Danaher team.”